Table 1.
Baseline participant characteristics of CAROLINA trial.6
| Linagliptin (n = 3023) N (%) |
Glimepiride ((n = 3010) N (%) |
|
|---|---|---|
| Age, mean (SD) years | 63.9 (9.5) | 64.2 (9.5) |
| Age > 70 years | 566 (37.4) | 592 (19.7) |
| Duration of diabetes (median, Q1, Q3) years | 6.3 (3.0,11.1) | 6.2 (2.9, 10.9) |
| HbA1c | 7.2 (0.6) | 7.2 (0.6) |
| FPG | 140 (31) | 140 (30) |
| ASCVD (any) | 1272 (42.2%) | 1250 (41.7%) |
| Heart failure | 122 (4.1%) | 149 (5.0%) |
| eGFR (MDRD, ml/min/1.73m2) | ||
| Mean (SD) | 76.5 (19.7) | 77.0 (19.8) |
| > 90 | 693 (23.0) | 722 (24.1) |
| 60-89 | 1726 (57.3) | 1740 (58.0) |
| 30-59 | 576 (19.1) | 525 (17.5) |
| 15-29 | 13 (0.4) | 13 (0.4) |
| < 15 | 3 (0.1) | 0 |
SD: standard deviation, ASCVD: Atherosclerotic Cardiovascular Disease, eGFR: estimated Glomerular Filtration Rate, MDRD: Modification of Diet in Renal Disease, Q1, Q3: interquartile range, HbA1c: glycated hemoglobin